In another investigation of immunotherapy pertaining to cGAS and gastric cancer, it was found that anlotinib treatment, a tyrosine-kinase inhibitor used in various solid tumors, leads to downregulation of programmed cell death ligand (PD-L1) and activation of the cGAS/STING pathway in gastric cancer cells (Yuan et al., 2022). The gene discussed is CGAS; the disease is gastric cancer.